news
Elysium Health Adds Six Peptides Following Updated HHS Policy Guidance
Elysium Health expanded its clinical catalog to include six therapeutic peptides alongside new research programs under recent HHS policy revisions. The expansion shifts the longevity brand beyond oral NAD boosters into physician-guided peptide protocols for cellular repair and metabolic signaling.
Elysium Health expanded its clinical catalog to include six therapeutic peptides alongside new research programs under recent HHS policy revisions. The expansion shifts the longevity brand beyond oral NAD boosters into physician-guided peptide protocols for cellular repair and metabolic signaling.
The architecture take
I used to think Elysium would stick safely to NAD precursors and academic patent filings forever. I was wrong, because consumer demand for bio-identical signaling molecules blew that quiet playbook wide open. Adding six peptides to their roster under the revised HHS policy shifts them straight into clinical longevity territory. Peptides like BPC-157 or growth hormone secretagogues do something specific at the cellular level: they prompt targeted tissue repair, nudge mitochondrial turnover, or signal the pituitary to release growth hormone pulses without shutting down your baseline production. That matters because the grey market for research chemicals is notoriously messy, underdosed, and full of static. Elysium is betting that nervous customers will happily pay a premium for verified purity and clinical oversight (and they usually will). Regulation moves slowly here. I suspect this move will force mid-tier supplement outfits to pick a lane: stay an inert multivitamin seller or start acting like a compounding pharmacy.